Use of Localized NB-UVB (Levia®) in the Treatment of Plaque-psoriasis

This will be an ascending dose study with treatments three times per week, initial treatment
dose and increasing regimen is adjusted according to the subject skin type. A suggested
treatment regimen schedule provided from Lerner Medical Devices, Inc:

For subjects with skin type I: starting dose of 195 mj/cm2, for subjects with skin type II:
starting dose of 330 mj/cm2, for subjects with skin type III: starting dose of 390 mj/cm2,
for subjects with skin type IV: starting dose of 495 mj/cm2, for subjects with skin type V:
starting dose of 525 mj/cm2, for subjects with skin type VI: starting dose of 600 mj/cm2.

The dose will be increased by 15% with each treatment, as long as there are no side effects
with treatment such as burning or redness.

Inclusion Criteria:

- Adults 18 years or older with bilateral psoriasis plaques, in general good health as
determined by the Principal Investigator by medical history and physical exam.

- Able to understand consent procedure

- Able to comply with protocol activities

- Must have baseline symmetric target lesions with baseline Target Lesion Score (TLS)
of 6 or higher (scale of 0-12), i.e., moderate in intensity for each target.

Target Lesion Scoring: Thickness, scaling and erythema of the plaques are rated each on a
scale of 0-4. The three scores are summed. The minimum score is 0; the maximum is 12.
Scores of 6 or greater are considered moderate to severe.

Exclusion Criteria:

- Patients less than 18 years old

- Patients not able to understand consent procedure

- Patients unable to comply with protocol activities

- Non-English speakers: the study assessments/questionnaires/evaluations are not
scientifically validated in languages other than English

- Baseline target lesions scores of less than 6

- Patients with a photosensitive disorder or on a medication which has been
demonstrated in these patients to cause photosensitivity

- Patients receiving concomitant phototherapy to test sites

- Patient receiving topical medication to test sites within 2 weeks of study initiation

- Patient receiving Methotrexate, Acitretin, Cyclosporine, or other oral medications
for psoriasis within 4 weeks of study initiation

- Patients receiving Etanercept (Enbrel®) within the past 2 months of study initiation

- Patients receiving Infliximab (Remicade®), Ustekinumab (Stelara®), Golimumab
(Simponi®) Adalimumab (Humira®) or Alefacept (Amevive®) within the past 3 months
prior to study initiation

- Receipt of an investigation agent within the past 4 weeks (or within 5 half lives)
prior to study ignition

- Systemic corticosteroid therapy within the past month

- Concurrent use of prohibited medications